Table 2. Analysis of acute prostatitis cases in different prophylactic treatment regimes of transrectal postate biopsy. ESBL-Producing E. Coli: Extended-spectrum Beta-lactamase and Quinolone-resistant Escherichia Coli.
| Ciprofloxacin group | Ciprofloxacin+ornidazole+ cleansing enema group | |
|---|---|---|
| Acute Prostatitis, n (%) | 22 (1.4) | 17 (0.8) |
| Symptoms starting time, days | 1.28 | 1.32 |
| Hospitalization time, day (mean±SD) | 4.76±3.20 | 4.87±3.40 |
| First Prostate Biopsy (n/N) | 16/1320 | 12/1722 |
| Second Prostate Biopsy (n/N) | 6/203 | 5/234 |
| Comorbidities | ||
| HT | 5 | 4 |
| DM | 4 | 3 |
| Bacteria Culture | ||
| Positive urinary culture, n (%) | 7 (31.8) | 8 (47) |
| Positive blood culture, n (%) | 6(27.2) | 7 (41) |
| ESBL- Producing E. Coli, n (%) | 4 (18) | 6 (35) |
| Blood culture ± | 3/1 | 5/1 |